A single injection of a gene therapy was well tolerated and showed the potential to control exudation in patients with neovascular age-related macular degeneration (wet AMD). A single subretinal dose ...
Majority of patients demonstrated successful efficacy readouts across structural measurements (foveal schisis closure) and had meaningful improvement on visual function measurements including MP, BCVA ...
These results demonstrate the clinical feasibility of an autonomous intraocular microsurgical robot and its ability to ...
CARLSBAD, Calif.--(BUSINESS WIRE)-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, ...
Please provide your email address to receive an email when new articles are posted on . Ocugen has announced that dosing is complete in the second cohort of its phase 1/2 ArMaDa clinical trial to ...
Ocugen, Inc. (OCGN) has two upcoming data readouts expected in 2024, both of which could drive shareholder value higher. This would be regarding the use of OCU-410 and OCU-410ST, which are being ...
“Currently, there is a lack of evidence-based research and rigorous guidelines for the management of patients with SMH secondary to nAMD [neovascular AMD],” said Dr. Gabrielle, who is based at the ...
Most retina specialists use a treat-and-extend approach for wet age-related macular degeneration (AMD), whereby anti–vascular endothelial growth factor (VEGF) injections are performed until the retina ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results